Loading...
•
Jun 30
PDS Biotechnology Q2 2025 Earnings Report
PDS Biotech reported a wider net loss in Q2 2025 due to increased net interest expenses, while operating expenses decreased slightly year-over-year.
Key Takeaways
Despite clinical advancements, PDS Biotech's Q2 2025 results reflected financial pressure from rising interest expenses. Operating costs were trimmed slightly, but the net loss deepened compared to Q2 2024.
Net loss widened to $9.4 million in Q2 2025, up from $8.3 million in Q2 2024.
EPS improved slightly to $(0.21) despite higher net interest expenses.
Operating expenses dropped to $7.6 million due to reduced G&A and R&D costs.
Cash and equivalents decreased to $31.9 million from $41.7 million at year-end.
PDS Biotechnology
PDS Biotechnology
Forward Guidance
PDS Biotech remains focused on advancing its clinical pipeline, with expansion triggered in key trials. Cash runway and financing remain key focus areas.
Positive Outlook
- Phase 3 VERSATILE-003 trial continues progress in HPV16+ head and neck cancers.
- Positive data from VERSATILE-002 presented at ASCO 2025.
- Colorectal cancer cohort in NCI-led trial met criteria to expand to Stage 2.
- Universal flu vaccine showed promising preclinical immune response.
- Company expects to publish full VERSATILE-002 dataset later in 2025.
Challenges Ahead
- Net loss increased due to rising interest expenses.
- Cash balance declined by $9.8 million since year-end 2024.
- Ongoing need for future financing to sustain operations.
- No commercial revenue reported yet.
- High accumulated deficit continues to grow.